MLD was founded in 2015. In November of 2016, MLD acquired all of the assets and intellectual property of Phenomenome Discoveries Inc. and Phenomenome Laboratory Services Inc. Our goal is to commercially advance our cancer risk assessment tests (Cologic® and PanaSeeTM), our Alzheimer's risk screening test (Alz-ID®), and the plasmalogen replacement therapeutic programs for Alzheimer's disease, Multiple Sclerosis, Parkinson's disease, and Plasmalogen Biogenesis Disorders including RCDP.